Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials

OBJECTIVE: In phase II and III trials, anifrolumab, a human monoclonal antibody that binds type I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We evaluated the safety and tolerability of anifrolumab using data pooled from these trials to more precisely est...

Descripción completa

Detalles Bibliográficos
Autores principales: Tummala, Raj, Abreu, Gabriel, Pineda, Lilia, Michaels, M Alex, Kalyani, Rubana N, Furie, Richard A, Morand, Eric F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical Trials and Drug Discovery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893670/
https://www.ncbi.nlm.nih.gov/pubmed/33597205
http://dx.doi.org/10.1136/lupus-2020-000464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893670/
https://www.ncbi.nlm.nih.gov/pubmed/33597205
http://dx.doi.org/10.1136/lupus-2020-000464

Ejemplares similares